Zim Laboratories Limited

Zim Laboratories reported a total operating income of INR718 million in Q1 FY26, marking a 12.3% year-on-year decline from INR818 million in Q1 FY25. This led to a significant impact on profitability, with EBITDA falling by 36.7% year-on-year to INR57 million, resulting in an EBITDA margin of 7.9%. The company recorded a net loss of INR19 million for the quarter, a stark contrast to the profit of INR9 million in the same period last year, primarily due to lower top line and increased depreciation and finance costs.

The company's facility underwent an EU-GMP inspection ahead of the launch of Oral Thin Films in Germany, which concluded with two critical and several major observations. These observations were primarily related to documentation problems and reliance on manual systems, not direct product quality issues. Management is engaging external experts and plans to submit a corrective and preventive action (CAPA) plan by August 31, 2025, with implementation expected to take at least six months. The UK program is not expected to be affected as it's an independent entity post-Brexit.

Softer order inflows in the innovation-led segment and geopolitical events in key Middle East markets significantly impacted the Q1 FY26 performance. This led to deferments and supply challenges, particularly in the MENA region, contributing to the 15.2% year-on-year decline in export revenue to INR602 million. However, management expects the situation to normalize, with compensation for lost sales anticipated in the next two quarters, and the business in the Middle East is considered sticky despite periodic turbulence.

Zim Laboratories maintains a strong development pipeline with 12 New Innovative Products (NIPs) in progress, 8 of which have been filed in the EU. While commercialization for many new products was initially expected in the last quarter of the previous financial year, these milestones have been delayed by approximately 3 to 6 months, now anticipated to happen in FY26. The company expects many products to enter various markets, including regulated ones, within 9 to 12 months, and the Neuraxpharm partnership launch is slated for the second half of the current financial year (Calendar year '26).

The company allocated INR79 million to R&D in Q1 FY26, with INR19 million specifically for Bioequivalence studies and registrations to advance the innovative product pipeline. Management emphasized that R&D investment is crucial for long-term growth, acknowledging the extended development cycles in the pharmaceutical industry. Despite near-term headwind^📎s, the company remains confident in its diversified market presence, strong partnerships, and disciplined execution to navigate challenges and achieve its long-term growth strategy.

Pharmaceuticals remained the cornerstone of the top line, contributing approximately 78% of the revenue, while the Nutra segment accounted for 22%. The year-on-year drop in Nutra revenue was mainly attributed to lower Nutra PFI business in the MENA region. In contrast to the export decline, the Indian business demonstrated robust growth of 30.2% year-on-year, reaching INR100 million, driven by higher value-added institutional business. Income from licensing also showed steady progress, contributing INR40 million from NIP licenses.